Clinical Trials Logo

SLE clinical trials

View clinical trials related to SLE.

Filter by:

NCT ID: NCT06445127 Recruiting - Lupus Nephritis Clinical Trials

Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)

Start date: May 7, 2024
Phase: N/A
Study type: Interventional

This study is being done to find out if a non-invasive Magnetic Resonance Imaging (MRI) examination of the kidneys may be helpful for diagnosing lupus nephritis in patients with systemic lupus erythematosus (SLE). Participation involves having a kidney MRI that will take between 30 to 60 minutes. Participants may have 1-4 kidney MRIs over a 6-month time period.

NCT ID: NCT06182969 Not yet recruiting - SLE Clinical Trials

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Start date: December 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).

NCT ID: NCT05966480 Recruiting - SLE Clinical Trials

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

LUMUS
Start date: June 26, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.

NCT ID: NCT05958446 Recruiting - Pregnancy Related Clinical Trials

Fetal-Hope Study: Home Monitoring of Fetal Heart Rate in SSA+ Pregnant Women

FH
Start date: April 14, 2022
Phase:
Study type: Observational

Serological positivity for anti Ro-SSA antibodies is frequently found in pathologies such as Sjogren's Syndrome and SLE. Worldwide, approximately 0.5-1% of women of reproductive age are positive for Ro-SSA antibodies, and in 1-2% of these women, pregnancy will be complicated by cardiac abnormalities of the fetus, particularly varying degrees of atrioventricular block. It is essential to promptly identify patients with fetal heart rhythm abnormalities to prevent both intrauterine deaths and the birth of newborns with third-degree atrioventricular block, requiring lifelong cardiac pacing. At the moment, the only means to identify these alterations is represented by fetal cardiac ultrasound. Fetal atrioventricular block can develop within a few hours in these patients and fetal ultrasound, normally performed no more frequently than once every two weeks, does not allow for the timely identification of these conditions and therefore for pharmacological intervention. Using home fetal heart rate monitoring, carried out directly by patients three times a day with the aid of a special device that allows easy identification of the fetal heart rhythm, would allow rapid recognition of rhythm alterations and early access to confirmation tests and possible therapies. Fetal heart rhythm surveillance could detect a medically reversible disease that, if untreated, would progress to lifelong cardiac pacing, with its many associated comorbidities. Applying such protocol in pregnant women anti-Ro/SSA positive could become standard practice. The main objectives of this study are: - Estimation of the incidence of the development of fetal AV conduction abnormalities in patients with positivity for Ro/SSA autoantibodies; - Estimation of the reliability of home monitoring of fetal heart rate with fetal Doppler device in detecting fetal atrioventricular conduction disturbances; - Evaluation of the results of the therapy administered early, immediately after the diagnosis of fetal atrioventricular conduction disorders.

NCT ID: NCT05822219 Recruiting - COVID-19 Clinical Trials

Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases

Start date: March 13, 2024
Phase: N/A
Study type: Interventional

To establish the efficacy of a community-based POL (Popular Opinion Leader) intervention with two different trainings designed to increase COVID-19 vaccine and booster uptake and reduce hesitancy among social networks of Black individuals with rheumatic conditions. The investigators will also determine the structure and composition of the personal and outreach social networks of POLs.

NCT ID: NCT05748925 Active, not recruiting - Lupus Nephritis Clinical Trials

Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients

Start date: October 1, 2022
Phase: Phase 4
Study type: Interventional

This study aims to assess sodium glucose linked transoprter inhibitors(SGT2i) role in regression of ongoing kidney and cardiac diseases among lupus nephritis patient either diabetic or non-diabetic under different immunosuppressive therapy. The main objective of this study is to: To compare use of sodium glucose linked transoprter inhibitors (SGLT2i) versus standard care in regression of chronic kidney disease in patient with lupus nephritis (LN). To study the safety and efficacy of this drug group with use of immunosuppression and possible interaction. Patients with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73m2 will be randomized into two groups Study group will receive SGLT2i inhibitor as add on drug or replace another drug according to patient clinical situation, Dapagliflozin 10 mg and 25 mg will be used once daily with or without food. Control group will be maintained on placebo.We will follow up all patients for 12 months and compare their results.

NCT ID: NCT05479071 Not yet recruiting - SLE Clinical Trials

Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.

Start date: September 1, 2022
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to correlate the autoantibody against oxidized LDL with disease activity and cardiovascular affection in patients with SLE.

NCT ID: NCT05470569 Recruiting - SLE Clinical Trials

Argentinian Prospective Registry of Patients With Lupus

Start date: April 1, 2022
Phase:
Study type: Observational

In Latin America, information about patients with systemic lupus erythematosus (SLE) is limited. Multicenter studies are needed to obtain "real world data '' and to carry out longer follow-ups. The purpose of this project is to design a cohort of Argentinian patients with SLE to describe "our real setting" and to identify possible limitations in access to specialized consultations and treatments.

NCT ID: NCT05342285 Recruiting - Clinical trials for Cardiovascular Diseases

Flow Mediated Dilation in Association With Hyperuricemia

Start date: July 30, 2022
Phase:
Study type: Observational

Assess cardiovascular affection and subclinical atherosclerosis in patients with systemic lupus using the non invasive flow mediated dilation. evaluate the role of uric acid as independent marker of cardiovascular risk in systemic lupus patient

NCT ID: NCT05230316 Active, not recruiting - SLE Clinical Trials

Gynecological Symptoms and Health-related Quality of Life in Egyptian Women With SLE

Start date: January 15, 2022
Phase:
Study type: Observational

The purpose of our study was to Recognize gynecological symptoms and health-related quality of life in Egyptian women with systemic lupus erythematosus and evaluate the impact of duration of remission on QOL in SLE patients.